Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Ultraviolet-A light increases mitochondrial anti-viral signaling protein in confluent human tracheal cells via cell-cell signaling

Gabriela Leite a, Ali Rezaie a,b, Ruchi Mathur a,c, Gillian M. Barlow a, Gil Y. Melmed b, Mark Pimentel a,b,*

a Medically Associated Science and Technology (MAST) Program, Cedars-Sinai, Los Angeles, CA, USA
b Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai, Los Angeles, CA, USA
c Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Cedars-Sinai, Los Angeles, CA, USA

ARTICLE INFO
Keywords: Ultraviolet-A light Mitochondrial antiviral signaling (MAVS) protein Cell-cell signaling

ABSTRACT
Mitochondrial antiviral signaling (MAVS) protein mediates innate antiviral responses, including responses to certain coronaviruses such as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). We have previously shown that ultraviolet-A (UVA) therapy can prevent virus-induced cell death in human ciliated tracheal epithelial cells (HTEpC) infected with coronavirus-229E (CoV-229E), and results in increased intracellular levels of MAVS. In this study, we explored the mechanisms by which UVA light can activate MAVS, and whether local UVA light application can activate MAVS at locations distant from the light source (e.g. via cell-to-cell communication). MAVS levels were compared in HTEpC exposed to 2 mW/cm² narrow band (NB)-UVA for 20 min and in unexposed controls at 30–40% and at 100% confluency, and in unexposed HTEpC treated with supernatants or lysates from UVA-exposed cells or from unexposed controls. MAVS was also assessed in different sections of confluent monolayer plates where only one section was exposed to NB-UVA. Our results showed that UVA increases the expression of MAVS protein. Further, cells in a confluent monolayer exposed to UVA conferred an elevation in MAVS in cells adjacent to the exposed section, and also in cells in the most distant sections which were not exposed to UVA. In this study, human ciliated tracheal epithelial cells exposed to UVA demonstrate increased MAVS protein, and also appear to transmit this influence to confluent cells not exposed to UVA, likely via cell-cell signaling.

1. Introduction
The human body has various defense mechanisms against infections, the most well-known of which involve innate immune responses where immune cells are recruited to sites of infection via cytokine signaling [1,2]. Host intracellular responses to infection are also important, particularly in the defense against viruses. In the past decade, it has been discovered that mitochondria can mediate innate and adaptive immune responses via several mechanisms [3], including the production of mitochondrial anti-viral signaling (MAVS) protein [4].

The MAVS protein is primarily localized to the outer membrane of the mitochondria, and transduces signals from cytoplasmic retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs) that recognize viral RNA [4]. Specifically, after recognition and binding of viral components, the RLRs RIG-I and melanoma differentiation-associated gene 5 (MDA5) interact with MAVS, activating transcription factors that induce expression of proinflammatory factors and antiviral genes [4]. However, some viruses have developed mechanisms to antagonize the activation of MAVS and evade this innate immune response. For example, the SARS-CoV-2 transmembrane glycoprotein M is thought to antagonize MAVS, thus impairing MAVS-mediated innate antiviral responses [5].

We recently showed that application of UVA light, under specific conditions, to human ciliated tracheal epithelial cells infected with coronavirus-229E (CoV-229E), significantly improved cell viability and prevented virus-induced cell death, and that this was accompanied by decreases in the levels of CoV-229E spike (S) protein [6]. Moreover, cells treated with UVA light exhibited significantly increased levels of MAVS protein [6] and decreased levels of inflammatory cytokines [7]. This suggested that UVA may activate MAVS. Further, in a first-in-human clinical trial in ventilated subjects with coronavirus disease 2019 (COVID-19), a 20-min endotracheal UVA treatment daily for 5 days resulted in significantly decreased respiratory SARS-CoV-2 viral loads...
Interestingly, despite time-limited localized UVA therapy in this trial, average log10 changes in endotracheal viral load from baseline to day 6 was −3.2, suggesting a potential antiviral phenomenon beyond immediate localized effects.

In this study, we explore the effects of narrow band (NB)-UVA light on MAVS expression in uninfected human ciliated tracheal epithelial cells in vitro. We also explore whether the effects of UVA light were limited to cells directly exposed to UVA, or were also seen in cells not directly exposed to UVA.

2. Methods

2.1. NB-UVA effects on MAVS

Primary human tracheal epithelial cells isolated from the surface epithelium of human trachea (HTEpC, lot n° 4542019.11, PromoCell GmbH, Heidelberg, Germany) were cultured at 37 °C (5% CO2) in 60×15mm standard tissue culture dishes (cat. 351,007, Corning, NY, USA) with Airway Epithelial Cell Growth Medium (cat. C-21060, PromoCell) prepared with SupplementMix (cat. C-39165, PromoCell) and Gibco antibiotic-antimycotic solution (cat. 15,240,096, ThermoFisher Scientific, MA, USA).

Once the cells reached 105 cells per plate (30–40% confluency), HTEpC were washed 3 times with sterile 1× PBS pH 7.4 (cat. 10,010,072, ThermoFisher), and fresh media was added to each plate. Cells were exposed to 2 mW/cm² of NB-UVA for 20 min. The temperature of the medium/cells during exposure to NB-UVA was checked every 5 min during the experiments using an infrared thermometer (Lasergrip 774, ETEKCITY, CA, USA). Unexposed cells were used as controls. After 24 h, the cells were washed 3 times with sterile 1× PBS, pH 7.4, scraped from the culture dishes, and transferred to a 15 mL sterile tube. Cells were pelleted, and fresh Airway Epithelial Cell Growth Medium was added. A single sterile 5 mm stainless steel bead (Qiagen) was added to each tube, and cells were lysed by vortexing the tube for 5 min. Lysates from UVA-exposed and control HTEpC were transferred to a new 60 × 15 mm tissue culture dish containing 105 naive HTEpC (i.e. HTEpC that had never been exposed to UVA). Before receiving the lysate from UVA-exposed or control cells, naïve HTEpC were washed 3 times with sterile 1× PBS, pH 7.4. The PBS was completely removed, and 4 mL of the lysate from either UVA-exposed or control HTEpC were added to the naïve cells. After 24 h of incubation, the cells were washed 3× with sterile 1× PBS and were then lysed in the plate using 1 mL of RTL buffer from an AllPrep DNA/RNA/Protein isolation kit (Qiagen). Experiments were performed four times.

2.2. NB-UVA effects on MAVS signal transmission to unexposed UVA-naïve cells

To determine whether the activation of MAVS caused by exposure to NB-UVA light could be transmitted to naïve, unexposed HTEpC, and to begin to elucidate the mechanisms involved in this transmission, supernatants from NB-UVA exposed non-confluent cells were used to evaluate signal transmission via extracellular mediators, lysates from NB-UVA exposed non-confluent cells were used to evaluate signal transmission via intracellular (non-secreted) mediators, and NB-UVA exposed confluent cells were used to evaluate signal transmission via cell-to-cell signaling.

2.3. NB-UVA effects on MAVS signal transmission via extracellular mediators

Supernatants collected from UVA-exposed and control HTEpC from the previous experiment were transferred to a new 60 × 15 mm tissue culture dish containing 105 naive HTEpC (i.e. cells that were never exposed to UVA). Before receiving the supernatant from UVA-exposed or control cells, the naïve HTEpC were washed 3× with sterile 1× PBS, pH 7.4. The PBS was completely removed, and 4 mL of the supernatant collected from UVA-exposed or control HTEpC were added to the naïve cells. After 24 h of incubation, the cells were washed 3×, and were then lysed in the plate using 1 mL of RTL buffer from an AllPrep DNA/RNA/Protein isolation kit (Qiagen). Experiments were performed in triplicate.

2.4. NB-UVA effects on MAVS signal transmission via intracellular mediators

HTEpC were cultured at 37 °C (5% CO2) in 60×15mm standard tissue culture dishes (cat. 351,007, Corning, NY, USA) with Airway Epithelial Cell Growth Medium (cat. C-21060, PromoCell) that included SupplementMix (cat. C-39165, PromoCell) and Gibco antibiotic-antimycotic solution (cat. 15,240,096, ThermoFisher Scientific, MA, USA).

On the day of NB-UVA therapy, cells were washed twice with sterile 1× PBS pH 7.4, and fresh media was added. Each 150 mm dish containing a 100% confluent monolayer of HTEpC was divided longitudinally into four sections, designated as areas 1, 2, 3 and 4, respectively.
(Fig. 1). The NB-UVA emitting device was placed 2.3 cm from the bottom of the dish and approximately 2 mW/cm² of NB-UVA was applied to area 1 for 20 min (Supp Fig. 1). The temperature of the medium/cells during exposure to NB-UVA was checked every 5 min during the experiments using an infrared thermometer (LaserGrip 774, Extech, CA, USA). Experiments were performed four times.

To prevent UVA leakage to other parts of the plate during therapy, areas 2, 3 and 4 were covered with a sterile barrier which blocked the passage of light through the top and sides of the plate (Supp Fig. 1). During the course of the therapy NB-UVA intensity was constantly checked in unexposed areas (top, bottom, and sides) of the culture plates using a UV meter (SDL470, Extech, NH), to assure there was no UVA light in these areas (Supp Fig. 1). UVA-treated plates were then re-incubated at 37 °C (5% CO₂) for 24 h.

UVA-treated HTEpC plates were washed 3 times with sterile 1 × PBS, pH 7.4, before harvesting the cells. 10 mL of sterile 1 × PBS, pH 7.4, was added to the plate, and cells from area 4 were carefully scraped with a sterile Corning Cell Lifter (cat. 3008, Corning) and immediately transferred to a 15 mL sterile tube. Cells were pelleted at low speed (~1000 RPM) and lysed with 1 mL RTL buffer from an AllPrep DNA/RNA/Protein isolation kit (Qiagen).

The remaining HTEpC from areas 1, 2 and 3 (still attached to the plate) were washed 3 × with sterile 1 × PBS, pH 7.4. 10 mL of sterile 1 × PBS, pH 7.4, was added to the plate and cells from area 3 were carefully scraped and lysed as described above. The same process was used to harvest the cells from areas 2 and 1 (in this order).

2.6 Protein extraction and western blotting

AllPrep DNA/RNA/Protein Mini Kits (Qiagen) were used to extract total proteins from UVA-exposed and non-exposed HTEpC from all experiments, according to the manufacturer’s protocol. Total proteins were quantitated using Qubit Protein Assays (ThermoFisher) and equal loads of total protein were separated on a NuPAGE 4–12% Bis-Tris mini gel (NP0336BOX, ThermoFisher) and then transferred onto a Biotrace NT nitrocellulose membrane (27376-991, VWR). Total proteins were stained with Ponceau S solution (P7170, Sigma-Aldrich). The membrane was blocked with tris-buffered saline containing 3% bovine serum albumin (cat. A7030, Sigma-Aldrich) and 0.1% Tween 20 (P1379, Sigma-Aldrich) (TBS-T), and incubated overnight at 4 °C with mouse anti-MAVS antibody (1:200; SC-166583, Santa Cruz Biotechnology) diluted in blocking solution. After washing in TBS-T, the membrane was then overlain with horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG antibody (1:300; 5220-0286, SeraCare), washed in TBS-T, and exposed to enhanced chemiluminescence solution (RPN2235, GE Healthcare). Immunoreactive protein bands were imaged using an iBright FL1500 instrument (ThermoFisher) and analyzed using iBright Analysis software (ThermoFisher). Samples were normalized against total protein as determined from Ponceau S staining (MilliporeSigma, St. Louis, MO, US) [9–13].

2.7 Statistical analysis

Graph construction and statistical analysis were performed with GraphPad Prism V. 9 (GraphPad Software, CA, USA). For all experiments, immunoreactive MAVS bands from nitrocellulose membranes were normalized against total protein (Ponceau S) before statistical analysis, using iBright Analysis software (ThermoFisher). MAVS relative densities (obtained after normalization) were compared between groups applying a non-paired t-test. Comparisons between each area from experiments with 100% confluent cell cultures were performed using paired t-test and ANOVA test. Significance level was set at p < 0.05.

3. Results

3.1 Narrow band-UVA (NB-UVA) increases MAVS protein levels in human non-confluent and confluent tracheal epithelial cells

Levels of MAVS were analyzed in primary tracheal epithelial cells (HTEpC) at 30–40% confluency which were exposed to 2 mW/cm² NB-UVA for 20 min and in unexposed controls. Normalized MAVS levels, as detected by western blot, were increased in NB-UVA exposed cells when compared to unexposed controls (P = 0.0193, Fig. 2). In addition, when primary tracheal epithelial cells were grown in 100% confluent monolayers (as opposed to 30–40% confluency), normalized MAVS levels in area 1 were also significantly increased following exposure to 2 mW/cm² NB-UVA for 20 min, when compared to levels in unexposed monolayers (P = 0.0006, Supp Fig. 2).

3.2 MAVS is activated by cell-to-cell signaling after NB-UVA exposure

When naïve 30–40% confluent HTEpC were treated with supernatants from NB-UVA exposed 30–40% confluent HTEpC, no changes in MAVS levels were observed (P = 0.4022, Fig. 4). However, when naïve 30–40% confluent HTEpC were incubated with cell lysates from NB-UVA exposed 30–40% confluent HTEpC, normalized levels of MAVS tended to increase (Fig. 5, P = 0.1256).

Next, levels of MAVS were analyzed in different areas of culture plates containing 100% confluent monolayers of HTEpC, after only one part of the plate (area 1) was exposed to 2 mW/cm² NB-UVA for 20 min (Fig. 1). Normalized MAVS levels gradually increased from area 4 (farthest unexposed area) through area 1 (exposed to NB-UVA) (ANOVA P = 0.08, Fig. 6A,B), and there was a statistically significant increase in MAVS levels in area 1 (exposed to NB-UVA) when compared to unexposed area 4 (P = 0.0382, Fig. 6A,B). Importantly, levels of MAVS were also significantly increased in unexposed areas 2 and 3 when compared to controls from unexposed plates (P = 0.0289 and P = 0.0402 respectively, Fig. 6A). Normalized MAVS levels in area 4 (farthest unexposed area) also appeared to be higher than in controls, but did not reach statistical significance (P = 0.1262, Fig. 6A).

4. Discussion

In this study, we show that narrow band UVA light increases the expression of the MAVS protein in uninfected human ciliated tracheal

![Fig. 2. Normalized MAVS levels in 30–40% confluent HTEpC exposed to 2 mW/cm² NB-UVA for 20 min, and in unexposed controls.](image-url)
epithelial cells in vitro. In addition, in a confluent monolayer culture of these cells, the induction of MAVS protein is transmitted to cells not directly exposed to NB-UVA light. This transmission does not appear to be due to a secreted extracellular mediator, but more likely results from direct cell-to-cell signaling, and possibly a cytosolic mediator.

External UVA therapy has long been used in the treatment of skin conditions such as psoriasis, eczema and skin lymphoma, for which it is FDA-approved [14–17]. To explore the potential of internal UVA light therapy to treat microbial infections, we recently tested UVA efficacy against a variety of pathogens in vitro, and found that under controlled and monitored conditions, UVA light effectively reduced a variety of bacterial species (including *Klebsiella pneumoniae*, *Escherichia coli*, *Clostridoides difficile*, and others), the yeast *Candida albicans*, coxsackievirus group B, and CoV-229E [6]. Importantly, we found that human ciliated tracheal epithelial cells that were infected with CoV-229E and then treated with NB-UVA light in vitro exhibited increases in MAVS protein and survived infection [6]. These results suggested that the increased cell viability of CoV-229E-infected and UVA-treated cells, as compared to infected but untreated controls, might be due to activation of MAVS-mediated antiviral signaling pathways. In the present study, human ciliated tracheal epithelial cells were exposed to UVA light, without viral infection. The results confirmed that exposure to UVA light alone results in increased levels of the MAVS protein in these cells, demonstrating that this is a response to UVA light.

It is well recognized that the common cold, influenza and other viruses are seasonal and occur more often in winter and less in summer months. The mechanism for this is unclear, although data suggest that sunlight, and the production of vitamin D, may be important. Sunlight has historical importance in medicine – for example, during the H1N1 influenza pandemic of 1918–1919, it was suggested that the combination of access to sunlight and fresh air, together with strict hygiene and the use of face masks, may have lessened mortality among patients and staff at an ‘open-air’ hospital in Boston [18]. A systematic review of data regarding vitamin D levels and the current COVID-19 pandemic suggests that sunlight and elevated vitamin D levels may improve outcomes [19]. Although the trials selected for inclusion in the latter study had heterogeneous results, these and other historical data [18] suggest that exposure to sunlight, and thus to UVA, may be beneficial in combating viral infections.

Under normal physiologic conditions, MAVS protein levels are low, due in part to binding of human antigen R as well as microRNAs to elements in the 3′UTR of the MAVS mRNA [4]. Following recognition and binding of viral components, the N-terminal caspase recruitment

![Fig. 3. Normalized MAVS levels in 100% confluent HTEpC area 1 exposed to 2 mW/cm² NB-UVA for 20 min, and in unexposed monolayer controls.](image)

![Fig. 4. A – Normalized MAVS levels in 30–40% confluent naïve HTEpC treated with supernatants from 30 to 40% confluent NB-UVA exposed HTEpC, and in controls incubated with supernatants from unexposed 30–40% confluent HTEpC. B - Western blot of proteins extracted from 30 to 40% confluent naïve HTEpC treated with supernatant from 30 to 40% confluent NB-UVA exposed HTEpC (lanes 1, 2 and 3), and from controls treated with supernatant from 30 to 40% confluent unexposed HTEpC (lanes 4, 5 and 6).](image)
domains (CARDs) of RLRs are ubiquitinated and bind to the CARD of MAVS, leading to aggregation of MAVS and activation of proinflammatory cytokines and antiviral interferon genes [4]. However, viruses can also evade these pathways – for example, the membrane glycoprotein M of SARS-CoV-2, the virus which causes COVID-19 [20], can interact with MAVS and impair MAVS aggregation and activation of antiviral responses [5]. In our preclinical studies, tracheal cells that were infected with CoV-229E and treated with UVA light also exhibited decreases in CoV-229E spike protein [6], which suggested to us that UVA light might also be an effective treatment for SARS-CoV-2.

Fig. 5. A – Normalized MAVS levels in 30–40% confluent naïve HTEpC treated with lysates from 30 to 40% confluent NB-UVA exposed HTEpC, and in controls incubated with lysates from 30 to 40% confluent unexposed HTEpC. B – Western blot prepared directly from lysates of 30–40% confluent naïve HTEpC incubated with lysates from 30 to 40% confluent NB-UVA exposed cells (lanes 1 to 4) and from lysates of controls incubated with lysates from 30 to 40% confluent unexposed HTEpC (lanes 5 to 8).

Fig. 6. A – Normalized MAVS levels in 100% confluent HTEpC partially exposed to 2 mW/cm² NB-UVA for 20 min. Area 1 was directly exposed to NB-UVA, but areas 2, 3 and 4 were not exposed to NB-UVA. B – Western blot prepared from cell lysates of 100% confluent HTEpC from three experiments, exposed to NB-UVA (area 1 - lanes 1, 5 and 9) and from lysates of confluent HTEpC not exposed to NB-UVA from the same culture plate (area 2 - lanes 2, 6 and 10; area 3 - lanes 3, 7 and 11; area 4 - lanes 4, 8, and 12).
The primary site of SARS-CoV-2 infection is the ciliated epithelial cells, associated with downstream characteristic bilateral ground-glass opacities [21]. The acute respiratory viral infection and subsequent inflammatory responses can result in compromised pulmonary function [20,22–24] and death [25]. Secondary bacterial and fungal infections are also common, with ventilator-associated pneumonia (VAP) occurring in 31% of mechanically ventilated patients [26]. To test the safety and efficacy of UVA light as a potential treatment for SARS-CoV-2, we developed a novel UVA light emitting diode (LED)-based catheter device which can be inserted into an endotracheal tube to deliver UVA light in critically ill COVID-19 subjects [8]. In the first human study of mechanically ventilated COVID-19 subjects, all of whom had World Health Organization (WHO) symptom severity scores of 9 at baseline (10 is death) [27], subjects who were treated with endotracheally-delivered UVA light (treated for 20 min daily for 5 days) exhibited an average log_{10} decrease in SARS-CoV-2 viral load of 3.2 (p < 0.001) by day 6 of therapy in endotracheal aspirates, and these accelerated reductions in viral loads correlated with 30-day improvements in the WHO symptom severity score [8]. Moreover, the scale of the improvements, despite the fact that only small portions of the trachea were exposed to UVA light, suggested the possibility that the antiviral effects of UVA light might not be confined to cells directly exposed to UVA, but might also be transmitted to neighboring cells.

To explore if this transmission was associated with secreted mediators present in the supernatant, we first took supernatants from UVA-exposed cells and added them to fresh plates of cells that were never exposed to UVA light. No increase in MAVS protein levels were seen in these cells, indicating that a secreted extracellular mediator was not involved. Next, to explore whether a non-secreted cytosolic mediator was involved, we lysed UVA-exposed cells and non-exposed controls and added the lysates to fresh plates of cells that were never exposed to UVA light. There was a trend towards an increase in MAVS protein levels in naïve HTEpC incubated with lysates from UVA-exposed cells, but this did not reach significance. In contrast, when we compared MAVS levels in confluent monolayers of HTEpC directly exposed to UVA light and in adjacent areas from the same plate that were blocked from UVA light, we found that MAVS was not only increased in cells in area 1 (directly exposed to UVA light), but was also increased in cells in the adjacent areas 2, 3, and 4 which were blocked from direct UVA light, in a gradient that decreased with increasing distance from UVA-exposed cells. These findings suggest that an increase in MAVS in response to UVA light can be transmitted from directly exposed cells to neighboring unexposed cells, and suggest that cell-to-cell signaling is involved, although further work is required to determine the mechanisms involved.

While this study is provocative, future studies are needed to explore the potential of UVA to enhance innate intracellular immunity to viruses. For example, as already stated, SARS-CoV-2 suppresses MAVS. Understanding the mechanisms by which UVA light overrides this suppression would be important. This could include damage to single-stranded viral RNA. In addition, the effects of this MAVS activation might be important to study with in vivo models. Limited data suggest that MAVS and resultant intracellular production of interferon α might attract circulating immune cellular response to attack infected cells [4]. We hypothesize that activation of MAVS in response to NB-UVA results in upregulation of signaling pathways involving IFNA1 and IRF3, thus ameliorating anti-viral responses consistent with our previous results [6]. Interestingly, in our previous in vitro study, CoV-229E caused precipitous cell death which was rescued with increased MAVS expression in response to UVA [6]. This increased cell survival suggests that perhaps MAVS is a cell salvage pathway. This is also supported by the first in human study of UVA in intubated critically ill subjects with COVID-19 [8]. Two patients underwent bronchoecopy after 5 days of UVA application. There was no macroscopic evidence of inflammation. Further studies are needed to explore these concepts not addressed in this current study.

In conclusion, this study begins to unravel one possible effect of UVA light on innate intracellular immunity. It appears that NB-UVA increases MAVS protein levels in human ciliated tracheal epithelial cells. This increase in MAVS protein appears to be transmissible to adjacent cells not directly exposed to UVA light. Further, our results suggest that MAVS signal transmission involves cell-to-cell communication, and possibly a cytosolic (but not a secreted extracellular) mediator. This finding may underlie the benefits of UVA seen in vitro and in human studies of critically ill patients with COVID-19. The findings could have wide-ranging implications for the treatment of SARS-CoV-2, other coronaviruses and other RNA respiratory viruses such as influenza. Further work is needed to determine if this mechanism is an important factor in the seasonality of specific respiratory viral illnesses.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

The authors thank Chadrinda Chatterjee for her assistance in preparing the figures. In addition, the authors thank the Monica Lester Charitable Trust and the Elias, Genevieve, and Georgianna Atal Charitable Trust for their support of the MAST Program’s COVID-19 research. These sponsors had no role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jphotobiol.2021.112357.

References

[1] J.V. Sarma, P.A. Ward, The complement system, Cell Tissue Res. 343 (1) (2011) 227–235. Epub 2010/09/15, https://doi.org/10.1007/s00441-010-1034-0. PubMed PMID: 20838815; PubMed Central PMCID: PMC30097465.
[2] N.S. Merle, R. Noe, I. Halbwachs-Mecarelli, V. Fremeaux-Bacchi, L.T. Roumenina, Complement system part II: role in immunity, Front Immunol. 6 (2015) 257. Epub 2015/06/16, https://doi.org/10.3389/fimmu.2015.00257. PubMed PMID: 26079922; PubMed Central PMCID: PMCPMC4443744.
[3] A. Mohanty, R. Tiwari-Pandey, N.R. Pandey, Mitochondria: the indispensable players in innate immunity and guardians of the inflammatory response, J. Cell Commun Signal. 13 (3) (2019) 303–318. Epub 2019/02/06, https://doi.org/10.1007/s40279-019-00507-9. PubMed PMID: 30719617; PubMed Central PMCID: PMCPMC6732146.
[4] Z. Ren, T. Ding, Z. Yao, Z. Xu, J. Deng, Z. Wei, Regulation of MAVS expression and signaling function in the antiviral innate immune response, Front Immunol. 11 (2020) 1030. Epub 2020/06/17, https://doi.org/10.3389/fimmu.2020.01030. PubMed PMID: 32536927; PubMed Central PMCID: PMCPMC7267026.
[5] Y.Z. Fu, S.Y. Wang, Z.Q. Zheng, H.Y. Li, W.W. Li, Z.S. Xu, et al., SARS-CoV-2 membrane glycoprotein M antagonizes the MAVS-mediated innate antiviral response, Cell Mol. Immunol. (2020), https://doi.org/10.1038/s41423-020-00571-x. Epub 2020/10/29. PubMed PMID: 33110251; PubMed Central PMCID: PMCPMC7588591.
[6] A. Rezaie, G.G.S. Leite, G.Y. Melmed, R. Mathur, M.J. Villanueva-Millan, G. Parodi, et al., Ultraviolet A light effectively reduces bacteria and viruses including coronavirus, PLoS One 15 (7) (2020), e0236199. Epub 2020/07/17, https://doi.org/10.1371/journal.pone.0236199. PubMed PMID: 32673355; PubMed Central PMCID: PMCPMC7365468.
[7] G. Leite, M. Fimentel, R. Mathur, G.M. Barlow, Y. Chan, G.Y. Melmed, et al., Ultraviolet-A light reduces cellular cytokine release from human endotracheal cells infected with Coronavirus, Photodiagn. Photodyn. Ther. 35 (2021) 102457. Epub 2021/07/28, https://doi.org/10.1016/j.pjpt.2021.102457. PubMed PMID: 34314863; PubMed Central PMCID: PMCPMC3310417.
[8] A. Rezaie, G.Y. Melmed, G. Leite, R. Mathur, W. Takakura, I. Pedraza, et al., Endotracheal application of ultraviolet A light in critically ill severe acute respiratory syndrome coronavirus-2 patients: a first-in-human study, medRxiv (2021), https://doi.org/10.1101/2021.03.05.21252997, 2021.03.05.21252997.
[9] H. Sander, S. Wallace, R. Ploune, S. Tiwari, A.V. Gomes, Ponceau S stain for total protein normalization, Anal. Biochem. 575 (2019) 44–53. Epub 2019/03/28, https://doi.org/10.1016/j.ab.2019.03.010. PubMed PMID: 30934243; PubMed Central PMCID: PMCPMC6954006.
J.S. Thacker, D.H. Yeung, W.R. Staines, J.G. Mielke, Total protein or high-abundance protein: which offers the best loading control for Western blotting? Anal. Biochem. Epub 2015/12/27 (496) (2016) 76-78, https://doi.org/10.1016/j.ab.2015.10.022 (PubMed PMID: 26706797).

I. Romero-Calvo, B. Ocion, P. Martínez-Moya, M.D. Sáezrez, A. Zarrueco, O. Martínez-Augustin, et al., Reversible Ponceau staining as a loading control alternative to actin in Western Blot, Anal. Biochem. 401 (2) (2010) 318-320. Epub 2010/03/09.

G.M. Aldridge, D.M. Podrebarac, W.T. Greenough, I.J. Weiler, The use of total protein stains as loading controls: an alternative to high-abundance single-protein controls in semi-quantitative immunoblotting, J. Neurosci. Methods 172 (2) (2008) 250-254. Epub 2008/06/24, https://doi.org/10.1016/j.jneumeth.2008.05.003. PubMed PMID: 18571732; PubMed Central PMCID: PMCPMC2567873.

L. Pillai-Kastoori, A.R. Schutz-Geschwender, J.A. Harford, A systematic approach to quantitative Western blot analysis, Anal. Biochem. 593 (2020) 113608. Epub 2020/02/03.

T. Bhutani, W. Liao, A practical approach to home UVB phototherapy for the treatment of generalized psoriasis, Pract. Dermatol. 7 (2) (2010) 31-35. Epub 2010/08/01. PubMed PMID: 25191138; PubMed Central PMCID: PMCPMC4151182.

P. Zhang, M.X. Wu, A clinic al review of phototherapy for psoriasis, Lasers Med. Sci. 33 (1) (2018) 173-180. Epub 2017/10/27, https://doi.org/10.1007/s10103-017-2360-1. PubMed PMID: 29067616; PubMed Central PMCID: PMCPMC5756569.

A. Patrizi, B. Raone, G.M. Ravaiolì, Safety and efficacy of phototherapy in the management of Eczema, Adv. Exp. Med. Biol. 996 (2017) 319–331. Epub 2017/11/11.

E.S. Tarabadkar, M.M. Shinhara, Skin directed therapy in cutaneous T-cell lymphoma, Front Oncol. 9 (2019) 260. Epub 2019/04/30, https://doi.org/10.3389/fonc.2019.00260. PubMed PMID: 31032224; PubMed Central PMCID: PMCPMC6470180.

R.A. Hobday, J.W. Cason, The open-air treatment of pandemic influenza, Am. J. Public Health 99 (Suppl. 2) (2009), https://doi.org/10.2105/AJPH.2008.134627, S236-42. Epub 2009/05/23. PubMed PMID: 19461112; PubMed Central PMCID: PMCPMC4504358.

H. Visak, A. Ewuemat, B. Kefale, M. Mamuye, F. Teshome, et al., Effects of vitamin D on COVID-19 infection and prognosis: a systematic review, Risk Manag. Healthc Policy 14 (2021) 31–38. Epub 2021/01/16, https://doi.org/10.2147/RMHP.S291584. PubMed PMID: 33447107; PubMed Central PMCID: PMCPMC7800698.

C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet 395 (10223) (2020) 497-506. Epub 2020/01/28.

F. Song, N. Shi, F. Shao, Z. Zhang, J. Shen, H. Lu, et al., Emerging 2019 novel coronavirus (2019-nCoV) pneumonia, Radiology 295 (1) (2020) 210–217. Epub 2020/02/07, https://doi.org/10.1148/radiol.2020200274d. PubMed PMID: 32025773; PubMed Central PMCID: PMCPMC7233366.

Z. Xu, L. Shi, Y. Wang, J. Zhang, L. Huang, C. Zhang, et al., Pathological findings of COVID-19 associated with acute respiratory distress syndrome, Lancet Respir. Med. 8 (4) (2020) 420-422. Epub 2020/02/23.

N. Chen, M. Zhou, X. Dong, J. Qu, F. Gong, Y. Han, et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet 395 (10223) (2020) 507–513. Epub 2020/02/03.

H. Shi, X. Han, N. Jiang, Y. Cao, O. Alwasil, J. Gu, et al., Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study, Lancet Infect. Dis. 20 (4) (2020) 425-434. Epub 2020/02/28, https://doi.org/10.1016/S1473-3099(20)30086-4. PubMed PMID: 32105637; PubMed Central PMCID: PMCPMC7159053.

G. Grasselli, A. Zangrillo, A. Zanella, M. Antonelli, L. Cabrini, A. Castelli, et al., Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy, JAMA (2020), https://doi.org/10.1001/jama.2020.5394. Epub 2020/04/07. PubMed PMID: 32250385; PubMed Central PMCID: PMCPMC7136855.

F. Zhou, T. Yu, R. Du, G. Fan, Y. Liu, Z. Liu, et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet 395 (10259) (2020) 1054–1062. Epub 2020/03/15.

infection WHOWGotCCaMoC, A minimal common outcome measure set for COVID-19 clinical research, Lancet Infect. Dis. 20 (8) (2020), https://doi.org/10.1016/S1473-3099(20)30483-7 e192-e7. Epub 2020/06/17. PubMed PMID: 32539996; PubMed Central PMCID: PMCPMC2925605.